Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David Molthrop"'
Autor:
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the patho
Externí odkaz:
https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55
Autor:
Masakazu Toi, Frances Boyle, Young-Hyuck Im, Mattea Reinisch, David Molthrop, Zefei Jiang, Ran Wei, Francisco Sapunar, Brenda R Grimes, Sarah Cassidy Nabinger, Stephen R D Johnston
Publikováno v:
The oncologist.
The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of
Autor:
Judy Dering, Linda D. Bosserman, Alejandra T. Perez, Christina Curtis, Jason J. Zoeller, Sara A. Hurvitz, Dennis J. Slamon, Ravindranath Patel, Gregory R. Bean, April Kennedy, Katherine McNamara, B DiCarlo, R Dichmann, Aruna Mani, Armando E. Giuliano, Eran Kotler, Joan S. Brugge, Carmen Calfa, Michael F. Press, Heather Allen, Hsiao Wang Chen, David Molthrop, Jennifer L. Caswell-Jin, Brad Adams, Lee Zehngebot
Publikováno v:
Nature communications, vol 11, iss 1
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications
In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials NCT00769470), participants with early-stage HER2-positive breast cancer (N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c071057d28a2c930749fdb77e63c624
https://escholarship.org/uc/item/5fs667t3
https://escholarship.org/uc/item/5fs667t3
Autor:
Chuan-gui Song, David Molthrop, Georgina Garnica Jaliffe, Joyce O'Shaughnessy, Maria Jose Muñoz, Masakazu Toi, Susana Barriga, Peter A. Fasching, Nadia Harbeck, Stephen Albert Johnston, Mahmut Gumus, Toshinari Yamashita, Valerie Andre, Michael Method, Desiree Headley, Priya Rastogi, Hans Kreipe, Ran Wei, Jacqueline Vuky, Miguel Martín
Publikováno v:
Cancer Research. 81:PD2-01
Background monarchE, a phase 3, open-label, randomized study evaluating endocrine therapy with or without abemaciclib in patients with node positive, HR+, HER2-, high risk early breast cancer, resulted in a statistically significant improvement in in
Autor:
Joan S. Brugge, Jason J. Zoeller, B DiCarlo, Judy Dering, H. Allen, Diego Martinez, Brad Adams, CJ Calfa, R Dichmann, S Hurvitz, H-w Chen, Aruna Mani, Ravindranath Patel, Alejandra T. Perez, David Molthrop, LM Zehngebot, A Kennedy, Linda D. Bosserman, Armando E. Giuliano, DJ Slamon, H-J Wang, JM Miller
Publikováno v:
Cancer Research. 73:S1-02
BACKGROUND: The BCIRG006 study (Slamon, et al. N Engl J Med 2011) demonstrated similar efficacy and superior safety of adjuvant docetaxel, carboplatin, and trastuzumab (TCH) over an anthracycline regimen in HER2+ BC. Dual HER2-blockade with lapatinib
Autor:
Maike Schmidt, Priti S. Hegde, Charles Ginther, Ling Fu, Sara A. Hurvitz, G. Upadhyaya, Daniel S. Chen, Giribala Patel, Eleonor Quan, John Barstis, Dennis J. Slamon, Michael P. Thirlwell, Maccon M. Keane, Steven H. Applebaum, David Molthrop, Mary Ann Allison, Ru-Fang Yeh, Linda D. Bosserman, Brian Leyland-Jones, Judy Dering, David C. Park, Brad Adams
Publikováno v:
Cancer Research. 72:1385-1385
Background: Bevacizumab (bev) has been widely studied in breast cancer (BC), yet no randomized trial in BC has reported in vivo molecular effects of bev on human tumor tissue. We conducted a trial to evaluate the safety, clinical & molecular effects